Investigational drug · Phase 2
Farletuzumab ecteribulin
Also called: MORAb-202
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "Farletuzumab ecteribulin"
First trial start
2020
Aug 6, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Farletuzumab ecteribulin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Farletuzumab ecteribulin" as an intervention, largest first.
Eisai Inc.Eisai
NCT04300556 · 182 participants (planned) · Start Aug 6, 2020 · Primary completion Aug 8, 2030
Drug: Farletuzumab ecteribulin; Prednisone and 3 more · For: Solid Tumor
Sites: Tucson, Arizona; Little Rock, Arkansas; Palo Alto, California · 58 sites in all
- A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05613088 · 106 participants · Start Feb 1, 2023 · Primary completion Jun 17, 2024
Drug: MORAb-202; Paclitaxel and 2 more · For: Neoplasms, Ovarian
Sites: Sacramento, California; San Francisco, California; Whittier, California · 50 sites in all
Eisai Inc.Eisai
NCT03386942 · 82 participants · Start Nov 28, 2017 · Primary completion Oct 26, 2022
Drug: Farletuzumab Ecteribulin · For: Solid Tumors
Sites: Matsuyama, Japan; Kurume, Japan; Sapporo, Japan · 10 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05577715 · 31 participants · Start Nov 14, 2022 · Primary completion Aug 12, 2024
Drug: MORAb-202 · For: Carcinoma, Non-Small-Cell Lung
Sites: Orange, California; Lone Tree, Colorado; Clermont, Florida · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.
Wenham RM, Ray-Coquard I, Kristeleit R, et al. · Gynecol Oncol 2026
- Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results.
Yonemori K, Yunokawa M, Matsumoto K, et al. · Int J Gynaecol Obstet 2026
- Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results.
Yoshida T, Kozuki T, Ikezawa H, et al. · JTO Clin Res Rep 2026
- Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys.
Fernando S, Mano Y · J Pharm Biomed Anal 2025
- Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.
Yagishita S, Sato S, Shintani D, et al. · Mol Cancer Ther 2025
- Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.
Hayato S, Hamuro L, Shimizu T, et al. · J Clin Pharmacol 2025
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.